Disproportionality analysis on hypothyroidism with roxadustat using the japanese adverse drug event database.

Hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) is a novel agent for the treatment of renal anemia. HIF-PHI increases endogenous erythropoietin production by inhibiting the degradation of an erythropoietin transcription factor. Although beneficial effects are expected from HIF-PHI, its novel mechanism raises concerns regarding the risk of potential adverse events. The cases of hypothyroidism, which had not been reported in clinical trials, has been reported after the administration of roxadustat in a real-world setting. However, the effects of HIF-PHIs on the thyroid function have not yet been fully evaluated. This study aimed to assess the clinical impact of HIF-PHIs on thyroid function using the Japanese Adverse Drug Event Report database (JADER), a spontaneous reporting system in Japan, because HIF-PHIs were made available in Japan prior to other countries. Although a disproportionality signal for hypothyroidism was detected with roxadustat (reporting odds ratio [ROR]:21.9, 95% confidence interval [CI]:18.2-26.3), no signals were detected with another HIF-PHI, daprodustat (ROR:1.6, 95%CI:0.5-5.0), and epoetin beta pegol (ROR:1.2, 95%CI:0.5-2.6). Signals of hypothyroidism due to roxadustat were also detected regardless of age or sex. Approximately 50% of hypothyroidism cases were reported within 50 days of starting roxadustat use. These results indicate that roxadustat use may be related to the development of hypothyroidism. The need for monitoring of thyroid function should be alerted during roxadustat administration regardless of age or sex. This article is protected by copyright. All rights reserved.